In this article, authors Tim Wilsdon, Artes Haderi, Zlatina Dobreva, and Giuliano Ricciardi discuss the potential impact of reforming Argentina’s innovation policy on innovative and economic activity. For their analysis, the authors review existing evidence on the relationship between changes in innovation policy and innovative activities to develop an analytical framework. Using that framework, they compare innovative activity in Argentina to other Latin American markets and case‐study markets in Asia that have experimented with innovation policy.
Finally, the authors explore how strengthening the policy environment could unlock Argentina’s potential and support a step change in innovative activity and the transition to a more knowledge‐intensive pharmaceutical industry. They conclude that this could be achieved by strengthening intellectual property rights relevant to the pharmaceutical and biotech industry and by providing regulatory data protection.
To read the article published in the Journal of World Intellectual Property, click here.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...